Jafron Biomedical Co

Jafron Biomedical Co Diluted EPS

The Diluted Earnings per Share of Jafron Biomedical Co (300529.SZ) as of Oct 21, 2026 is 0.67 CNY. In the previous year, Diluted Earnings per Share was 1.03 CNY — a change of -34.90% (lower).

Diluted EPS

0.67CNY

YoY

-34.90%

Last updated:

Diluted Earnings per Share of Jafron Biomedical Co is 2025 0.67 CNY. Diluted Earnings per Share of Jafron Biomedical Co was 2024 1.03 CNY. It decreases by -34.90% lower compared to the previous year.

The Jafron Biomedical Co Diluted EPS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Diluted EPS
Date
Diluted EPS
Jan 1, 2018
0.51 CNY
Jan 1, 2019
0.72 CNY
Jan 1, 2020
1.10 CNY
Jan 1, 2021
1.47 CNY
Jan 1, 2022
1.11 CNY
Jan 1, 2023
0.54 CNY
Jan 1, 2024
1.03 CNY
Jan 1, 2025
0.67 CNY
The Jafron Biomedical Co Diluted EPS history
YEARDiluted EPSYoY
0.67CNY-34.90%
1.03CNY+92.43%
0.54CNY-51.95%
1.11CNY-24.03%
1.47CNY+34.02%
1.10CNY+51.41%
0.72CNY+42.61%
0.51CNY+41.89%
0.36CNY+34.15%
0.27CNY-6.63%
0.29CNY+41.54%
0.20CNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Jafron Biomedical Co Stock analysis

What does Jafron Biomedical Co do? Jafron Biomedical Co., Ltd. generates revenue through the research, development, production, and sale of hemoperfusion products and medical equipment. The company offers a range of items including disposable hemoperfusion devices, hemoperfusion machines, disposable bilirubin adsorbers, the DX-10 blood purification machine, suture needles, and resins bandage. These products are utilized for treating conditions such as uremia, poisoning, severe liver diseases, autoimmune diseases, and multisystem organ failure. The primary customers for these medical solutions are hospitals across China, where the company’s products are applied in more than 3000 hospitals within 31 provinces. As a China-based company, Jafron Biomedical Co., Ltd. focuses on the design, manufacture, and distribution of biological materials and medical equipment to support healthcare providers in these regions. The company operates from its headquarters in Zhuhai, Guangdong, and supports its operations with a workforce of 3,003 full-time employees. By engaging in the full lifecycle of its products from research to sale, the firm serves the medical sector with specialized equipment for blood purification and related therapeutic needs. Jafron Biomedical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Jafron Biomedical Co stock

Diluted Earnings per Share of Jafron Biomedical Co is 0.67 CNY in 2025.

Diluted Earnings per Share of Jafron Biomedical Co changed from 1.03 CNY to 0.67 CNY, representing a -34.90% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Diluted Earnings per Share Jafron Biomedical Co since 2006 – with annual values, charts, and detailed analysis.

Diluted EPS accounts for all potential shares from options, warrants, and convertible securities. It provides a more conservative per-share earnings measure.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Jafron Biomedical Co

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Jafron Biomedical Co